US 12,295,985 B2
Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1)
Dong Feng Chen, Newtonville, MA (US); and Chenying Guo, Malden, MA (US)
Assigned to The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed by The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed on Dec. 2, 2022, as Appl. No. 18/073,951.
Application 18/073,951 is a continuation of application No. 17/070,596, filed on Oct. 14, 2020, abandoned.
Application 17/070,596 is a continuation of application No. 14/002,033, granted, now 10,842,849, issued on Nov. 24, 2020, previously published as PCT/US2012/026931, filed on Feb. 28, 2012.
Claims priority of provisional application 61/447,314, filed on Feb. 28, 2011.
Prior Publication US 2023/0277623 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/18 (2006.01); A61K 31/00 (2006.01); A61K 31/352 (2006.01); A61K 31/7004 (2006.01); A61K 31/708 (2006.01); A61K 31/7088 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 31/713 (2006.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 38/22 (2006.01); A61K 38/30 (2006.01); A61K 45/06 (2006.01); C07K 14/00 (2006.01); C07K 14/47 (2006.01); C07K 14/48 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 35/30 (2015.01); A61K 48/00 (2006.01); A61K 49/00 (2006.01); C12N 5/079 (2010.01); C12N 5/0797 (2010.01); G01N 33/50 (2006.01)
CPC A61K 38/18 (2013.01) [A61K 31/00 (2013.01); A61K 31/352 (2013.01); A61K 31/7004 (2013.01); A61K 31/708 (2013.01); A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 31/711 (2013.01); A61K 31/713 (2013.01); A61K 38/1738 (2013.01); A61K 38/1841 (2013.01); A61K 38/2278 (2013.01); A61K 38/30 (2013.01); A61K 45/06 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/0085 (2013.01); A61K 9/5169 (2013.01); A61K 35/30 (2013.01); A61K 38/1703 (2013.01); A61K 38/1709 (2013.01); A61K 38/22 (2013.01); A61K 48/00 (2013.01); A61K 49/0056 (2013.01); A61K 2300/00 (2013.01); C12N 5/0621 (2013.01); C12N 5/0623 (2013.01); C12N 2501/105 (2013.01); C12N 2502/08 (2013.01); C12N 2502/081 (2013.01); C12N 2533/50 (2013.01); G01N 33/5058 (2013.01); G01N 33/5073 (2013.01); Y02A 50/30 (2018.01)] 12 Claims
 
1. A method of reducing severity of glaucoma in a subject in need thereof, the method comprising intravitreally administering to the subject a composition comprising an insulin-like growth factor binding protein-like 1 (IGFBPL-1) protein.